Bill Sibold gets promotion at Sanofi

5 April 2017

French pharma major Sanofi (Euronext: SAN) has promoted Bill Sibold to the post of executive vice president Sanofi Genzyme, effective July 1, 2017. In this role, Mr Sibold will be a member of the executive committee.

He succeeds David Meeker, who will leave the company at the end of June after a distinguished 23-year career with Genzyme and Sanofi.

Mr Sibold currently serves as head of Sanofi Genzyme's global multiple sclerosis, oncology and immunology organization, a position he has held since January 2016 and where he has led preparation for the global launches of dupilumab and sarilumab. He joined Sanofi in late 2011 as head of the MS franchise where he oversaw the successful launches of Aubagio (teriflunomide) and Lemtrada (alemtuzumab). As head of Sanofi Genzyme, Mr Sibold will now lead the company's efforts to maintain its leadership in rare diseases while continuing to grow in multiple sclerosis, oncology and immunology.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK